Drug shortage: Remifentanil Hydrochloride Injection (REMIFENTANIL HYDROCHLORIDE, ULTIVA)
FDA lists 9 presentations as Current. Availability: Unavailable (4), Available (5). Reason: Demand increase for the drug; Delay in shipping of the drug. Companies: Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA, Inc., Mylan Institutional, a Viatris Company.
- Published by source
- 2022-06-28
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Fresenius Kabi USA, LLC
- Products
- Remifentanil Hydrochloride Injection REMIFENTANIL HYDROCHLORIDE ULTIVA
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Check wholesalers for inventory
- Estimated recovery: TBD
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2022-06-28
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #873 | new | 2026-10-22 | 8249d2c02759…0686d1 | 2396e20923a9…8b0b8d |
Chain head: #1094 edf3be25ec2e…478842